Tim Wright, Editor, Contract Pharma11.12.18
Contract Pharma asked Paolo Magrì, senior vice president, business development at Advitech Advisory and Technologies and president of the Drug, Chemical and Associated Technologies Association (DCAT), to discuss the major challenges of the pharmaceutical industry as well as key trends in the market for small molecules and biologic-based drugs.
Mr. Magrì has over 28 years of experience in the active pharmaceutical ingredient (API) sector. Prior to joining Advitech, he served as vice president of corporate business development at Infa Group. During his tenure (2005-2016), Infa grew by acquisition to include sites in Italy and Spain, and a contract manufacturing division. Prior to Infa, Mr. Magrì served as marketing and sales director at Sicor and in Teva’s API division, after the acquisition of Sicor by Teva in 2004.
His strong track record in the industry also includes previous roles at Archimica/Pro.Bio.Sint. and Fordras. Mr. Magrì earned h
FREE SUBSCRIPTION
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
